Radioimmunotherapy-based treatment of cancer

Document Type : Review Article


1 Department of Immunology and Allergy, Faculty of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran and Department of Immunology and Allergy, The Persian Gulf Tropical and Infectious Diseases Research Centre, Bushehr University of Medical Sciences, Bushehr, Iran and The Persian Gulf Nuclear Medicine Research Centre, Bushehr University of Medical Sciences, Bushehr, Iran

2 Department of Immunology and Allergy, The Persian Gulf Tropical and Infectious Diseases Research Centre, Bushehr University of Medical Sciences, Bushehr, Iran

3 Department of Immunology and Allergy, Faculty of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran and Department of Immunology and Allergy, The Persian Gulf Tropical and Infectious Diseases Research Centre, Bushehr University of Medical Sciences, Bushehr, Iran

4 Department of Endocrine and Metabolic Diseases, The Persian Gulf Tropical Medicine Research Center, Bushehr University of Medical Sciences, Bushehr, Iran

5 The Persian Gulf Nuclear Medicine Research Centre, Bushehr University of Medical Sciences, Bushehr, Iran


The principle of cancer immunotherapy includes various methods of manipulations to influence immune responses against tumors in both humans and animals. This advanced technology of hybridoma production provided the necessary skills to efficiently produce highly specific monoclonal antibodies (mAb). Radioactively-tagged antibodies which are applied in radioimmunotherapy (RIT), can target adjacent cells and may not require immune function. This study highlights the mechanism and the effect of action of radioimmunotherapic agents, especially two applied agents including 90Y-ibritumomab tiuxetan and 131I-tositumomab that are approved by Food and Drug Administration (FDA) for treatment of some cancers.


Main Subjects

Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res. 1991 Jan;(262):3-11.
Cantani A. Specific immunotherapy in children: past and present. Eur Rev Med Pharmacol Sci. 1999 Mar-Apr;3(2):93-5.
Cacciapaglia F, Spadaccio C, Chello M, Gigante A, Coccia R, Afeltra A, Amoroso A. Apoptotic molecular mechanisms implicated in autoimmune diseases. Eur Rev Med Pharmacol Sci. 2009 Jan-Feb;13(1):23-40.
Cantani A, Micera M. Is specific immunotherapy safe and effective in children? Eur Rev Med Pharmacol Sci. 2000 Sep-Dec;4(5-6):139-43.
Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975 Aug 7;256(5517):495-7.
Köhler G, Milstein C. Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. Eur J Immunol. 1976 Jul;6(7):511-9.
Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med. 2002 May;43(5):693-713.
Borghaei H, Smith MR, Campbell KS. Immunotherapy of cancer. Eur J Pharmacol. 2009 Dec 25;625(1-3):41-54.
Mathas S, Rickers A, Bommert K, Dörken B, Mapara MY. Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways. Cancer Res. 2000 Dec 15;60(24):7170-6.
Ruggiero A, Villa CH, Holland JP, Sprinkle SR, May C, Lewis JS, Scheinberg DA, McDevitt MR. Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes. Int J Nanomedicine. 2010 Oct 5;5:783-802.
DeNardo SJ, Kukis DL, Miers LA, Winthrop MD, Kroger LA, Salako Q, Shen S, Lamborn KR, Gumerlock PH, Meares CF, DeNardo GL. Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts. J Nucl Med. 1998 May;39(5):842-9.
Dreyling M, Hiddemann W; European MCL Network. Current treatment standards and emerging strategies in mantle cell lymphoma. Hematology Am Soc Hematol Educ Program. 2009:542-51.
Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, Leblanc M, Fisher RI; Southwest Oncology Group. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol. 2006 Sep 1;24(25):4143-9.
Leonard JP, Coleman M, Kostakoglu L, Chadburn A, Cesarman E, Furman RR, Schuster MW, Niesvizky R, Muss D, Fiore J, Kroll S, Tidmarsh G, Vallabhajosula S, Goldsmith SJ. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol. 2005 Aug 20;23(24):5696-704.
O'Donnell RT, DeNardo GL, Kukis DL, Lamborn KR, Shen S, Yuan A, Goldstein DS, Carr CE, Mirick GR, DeNardo SJ. A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma. J Nucl Med. 1999 Dec;40(12):2014-20.
van Zanten-Przybysz I, Molthoff CF, Roos JC, Plaizier MA, Visser GW, Pijpers R, Kenemans P, Verheijen RH. Radioimmunotherapy with intravenously administered 131I-labeled chimeric monoclonal antibody MOv18 in patients with ovarian cancer. J Nucl Med. 2000 Jul;41(7):1168-76.
Reilly RM. Radioimmunotherapy of solid tumors: the promise of pretargeting strategies using bispecific antibodies and radiolabeled haptens. J Nucl Med. 2006 Feb;47(2):196-9.
Wahl RL. Tositumomab and (131)I therapy in non-Hodgkin's lymphoma. J Nucl Med. 2005 Jan;46 Suppl 1:128S-40S.
Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood. 1984 Jun;63(6):1424-33.
Tedder TF, Boyd AW, Freedman AS, Nadler LM, Schlossman SF. The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol. 1985 Aug;135(2):973-9.
Jacene HA, Filice R, Kasecamp W, Wahl RL. Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice. J Nucl Med. 2007 Nov;48(11):1767-76.
Witzig TE. Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma. Drugs Today (Barc). 2004 Feb;40(2):111-9.
Hagenbeek A. Radioimmunotherapy for NHL: experience of 90Y-ibritumomab tiuxetan in clinical practice. Leuk Lymphoma. 2003;44 Suppl 4:S37-47.
Baechler S, Hobbs RF, Jacene HA, Bochud FO, Wahl RL, Sgouros G. Predicting hematologic toxicity in patients undergoing radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-tositumomab. J Nucl Med. 2010 Dec;51(12):1878-84.
Cardarelli PM, Quinn M, Buckman D, Fang Y, Colcher D, King DJ, Bebbington C, Yarranton G. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother. 2002 Mar;51(1):15-24.
Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J Immunol. 1980 Oct;125(4):1678-85.
Davis TA, Kaminski MS, Leonard JP, Hsu FJ, Wilkinson M, Zelenetz A, Wahl RL, Kroll S, Coleman M, Goris M, Levy R, Knox SJ. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res. 2004 Dec 1;10(23):7792-8.
Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S, Sparks RB, Stabin MG, Witzig T, White CA. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med. 2003 Mar;44(3):465-74.
Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-López AJ, Multani P, White CA. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002 May 15;20(10):2453-63.
Witzig TE, White CA, Gordon LI, Wiseman GA, Emmanouilides C, Murray JL, Lister J, Multani PS. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma. J Clin Oncol. 2003 Apr 1;21(7):1263-70.
Marcus R. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma. Semin Oncol. 2005 Feb;32(1 Suppl 1):S36-43.
Schilder R, Molina A, Bartlett N, Witzig T, Gordon L, Murray J, Spies S, Wang H, Wiseman G, White C. Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia. Cancer Biother Radiopharm. 2004 Aug;19(4):478-81.
Goldenberg DM, Rossi EA, Sharkey RM, McBride WJ, Chang CH. Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting. J Nucl Med. 2008 Jan;49(1):158-63.
Wiseman GA, Conti PS, Vo K, Schilder RJ, Gordon LI, Emmanouilides C, Silverman DH, Witzig TE, Darif M, Molina A. Weight-based dosing of Yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Clin Lymphoma Myeloma. 2007 Sep;7(8):514-7.
Gordon LI, Witzig T, Molina A, Czuczman M, Emmanouilides C, Joyce R, Vo K, Theuer C, Pohlman B, Bartlett N, Wiseman G, Darif M, White C. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymphoma. 2004 Sep;5(2):98-101.
Jacene HA, Filice R, Kasecamp W, Wahl RL. 18F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy. J Nucl Med. 2009 Jan;50(1):8-17.
Ansell SM, Ristow KM, Habermann TM, Wiseman GA, Witzig TE. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. J Clin Oncol. 2002 Sep 15;20(18):3885-90.
Emmanouilides C, Witzig TE, Gordon LI, Vo K, Wiseman GA, Flinn IW, Darif M, Schilder RJ, Molina A. Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. Leuk Lymphoma. 2006 Apr;47(4):629-36.
Schaefer NG, Ma J, Huang P, Buchanan J, Wahl RL. Radioimmunotherapy in non-Hodgkin lymphoma: opinions of U.S. medical oncologists and hematologists. J Nucl Med. 2010 Jun;51(6):987-94.
Juweid ME. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice. J Nucl Med. 2002 Nov;43(11):1507-29.
Delaloye AB, Antonescu C, Louton T, Kuhlmann J, Hagenbeek A. Dosimetry of 90Y-ibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial. J Nucl Med. 2009 Nov;50(11):1837-43.
Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, Regan D, Kison P, Fisher S, Kroll S, Wahl RL. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005 Feb 3;352(5):441-9.
Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL, Schilder RJ, Murray JL, Saleh M, Allen RS, Grillo-López AJ, White CA. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood. 2002 Jun 15;99(12):4336-42.
Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, Cripe L, Wiseman G, Olejnik T, Multani PS, White CA. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol. 2002 Aug 1;20(15):3262-9.
Gupta D, Crosby ME, Almasan A, Macklis RM. Regulation of CD20 expression by radiation-induced changes in intracellular redox status. Free Radic Biol Med. 2008 Feb 15;44(4):614-23.
Gopal AK, Rajendran JG, Gooley TA, Pagel JM, Fisher DR, Petersdorf SH, Maloney DG, Eary JF, Appelbaum FR, Press OW. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol. 2007 Apr 10;25(11):1396-402.
Krishnan A, Nademanee A, Fung HC, Raubitschek AA, Molina A, Yamauchi D, Rodriguez R, Spielberger RT, Falk P, Palmer JM, Forman SJ. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J Clin Oncol. 2008 Jan 1;26(1):90-5.
Montoto S, Canals C, Rohatiner AZ, Taghipour G, Sureda A, Schmitz N, Gisselbrecht C, Fouillard L, Milpied N, Haioun C, Slavin S, Conde E, Fruchart C, Ferrant A, Leblond V, Tilly H, Lister TA, Goldstone AH; EBMT Lymphoma Working Party. Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia. 2007 Nov;21(11):2324-31.
Sacchi S, Marcheselli L, Bari A, Marcheselli R, Pozzi S, Luminari S, Lombardo M, Buda G, Lazzaro A, Gobbi PG, Stelitano C, Morabito F, Quarta G, Brugiatelli M. Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study. Haematologica. 2008 Mar;93(3):398-404.
Gregory SA, Hohloch K, Gisselbrecht C, Tobinai K, Dreyling M. Harnessing the energy: development of radioimmunotherapy for patients with non-Hodgkin's lymphoma. Oncologist. 2009;14 Suppl 2:4-16.
Morschhauser F, Illidge T, Huglo D, Martinelli G, Paganelli G, Zinzani PL, Rule S, Liberati AM,
Milpied N, Hess G, Stein H, Kalmus J, Marcus R. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood. 2007 Jul 1;110(1):54-8.
Gisselbrecht C, Vose J, Nademanee A, Gianni AM, Nagler A. Radioimmunotherapy for stem cell transplantation in non-Hodgkin's lymphoma: in pursuit of a complete response. Oncologist. 2009;14 Suppl 2:41-51.
Wang M, Oki Y, Pro B, Romaguera JE, Rodriguez MA, Samaniego F, McLaughlin P, Hagemeister F, Neelapu S, Copeland A, Samuels BI, Loyer EM, Ji Y, Younes A. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009 Nov 1;27(31):5213-8.
Gopal AK, Rajendran JG, Petersdorf SH, Maloney DG, Eary JF, Wood BL, Gooley TA, Bush SA, Durack LD, Martin PJ, Matthews DC, Appelbaum FR, Bernstein ID, Press OW. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood. 2002 May 1;99(9):3158-62.
Smith-Jones PM, Pandit-Taskar N, Cao W, O'Donoghue J, Philips MD, Carrasquillo J, Konner JA, Old LJ, Larson SM. Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003. Nucl Med Biol. 2008 Apr;35(3):343-51.
Jakobovits A. Monoclonal antibody therapy for prostate cancer. Handb Exp Pharmacol. 2008;(181):237-56.
Goldenberg DM, DeLand FH, Bennett SJ, Primus FJ, Nelson MO, Flanigan RC, McRoberts JW, Bruce AW, Mahan DE. In vivo use of radioactive antibodies against prostatic acid phosphatase for diagnosis and detection of prostatic cancer by nuclear imaging. JAMA. 1983 Aug 5;250(5):630-5.
Meredith RF, Bueschen AJ, Khazaeli MB, Plott WE, Grizzle WE, Wheeler RH, Schlom J, Russell CD, Liu T, LoBuglio AF. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J Nucl Med. 1994 Jun;35(6):1017-22.
Gerke O, Poulsen MH, Bouchelouche K, Høilund-Carlsen PF, Vach W. PET/CT in cancer: moderate sample sizes may suffice to justify replacement of a regional gold standard. Mol Imaging Biol. 2009 Nov-Dec;11(6):381-5.
Pedley RB, Boden J, Keep PA, Harwood PJ, Green AJ, Rogers GT. Relationship between tumour size and uptake of radiolabelled anti-CEA in a colon tumour xenograft. Eur J Nucl Med. 1987;13(4):197-202.
Flynn AA, Green AJ, Boxer GM, Casey JL, Pedley RB, Begent RH. A novel technique, using radioluminography, for the measurement of uniformity of radiolabelled antibody distribution in a colorectal cancer xenograft model. Int J Radiat Oncol Biol Phys. 1999 Jan 1;43(1):183-9.
McDevitt MR, Chattopadhyay D, Kappel BJ, Jaggi JS, Schiffman SR, Antczak C, Njardarson JT, Brentjens R, Scheinberg DA. Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes. J Nucl Med. 2007 Jul;48(7):1180-9.
Kaminski MS, Zasadny KR, Francis IR, Milik AW, Ross CW, Moon SD, Crawford SM, Burgess JM, Petry NA, Butchko GM, et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med. 1993 Aug 12;329(7):459-65.
Vose JM, Wahl RL, Saleh M, Rohatiner AZ, Knox SJ, Radford JA, Zelenetz AD, Tidmarsh GF, Stagg RJ, Kaminski MS. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2000 Mar;18(6):1316-23.
Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H, Huijgens PC, Kolstad A, d'Amore F, Gonzalez Diaz M, Petrini M, Sebban C, Zinzani PL, van Oers MH, van Putten W, Bischof-Delaloye A, Rohatiner A, Salles G, Kuhlmann J, Hagenbeek A. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol. 2008 Nov 10;26(32):5156-64.
Schaefer NG, Huang P, Buchanan JW, Wahl RL. Radioimmunotherapy in non-Hodgkin lymphoma: opinions of nuclear medicine physicians and radiation oncologists. J Nucl Med. 2011 May;52(5):830-8.
Lopci E, Santi I, Tani M, Maffione AM, Montini G, Castellucci P, Stefoni V, Rubello D, Fonti C, Zinzani P, Fanti S. FDG PET and 90Y ibritumomab tiuxetan in patients with follicular lymphoma. Q J Nucl Med Mol Imaging. 2010 Aug;54(4):436-41.